
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Rosiglitazone | FAERS: 7 | US FAERS | |
| 2 | Fosamax plus D | FAERS: 2 | US FAERS | |
| 3 | carfilzomib | FAERS: 2 | US FAERS | |
| 4 | rofecoxib | FAERS: 2 | US FAERS | |
| 5 | Anastrozole | FAERS: 1 | US FAERS | |
| 6 | Atomoxetine Hydrochloride | FAERS: 1 | US FAERS | |
| 7 | Dexlansoprazole | FAERS: 1 | US FAERS | |
| 8 | Digoxin | FAERS: 1 | US FAERS | |
| 9 | Glatiramer Acetate | FAERS: 1 | US FAERS | |
| 10 | Sorafenib | FAERS: 1 | US FAERS | |
| 11 | fluticasone furoate | FAERS: 1 | US FAERS | |
| 12 | Clozapine | Canada Vigilance: 1 | Canada Vigilance |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120238
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.